, Volume 31, Issue 2, pp 125–136

A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination

Systematic Review



The varicella zoster virus (VZV) can cause two infections: chickenpox or herpes zoster (HZ). Whereas chickenpox infections are normally mild but common among children, HZ infections are common among elderly people and can give rise to post-herpetic neuralgia (PHN), a severe and painful complication.


This review aimed to summarize the literature available on the cost effectiveness of HZ vaccination and to summarize key issues for decision makers to consider when deciding on the reimbursement of HZ vaccination.


We conducted a literature search of the databases PubMed and EMBASE using EndNote X4 from Thomson Reuters. The following combinations of keywords were used: ‘herpes zoster vaccine’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’, ‘herpes zoster vaccination’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’, ‘varicella zoster vaccine’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’, and ‘varicella zoster vaccination’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’.


A total of 11 studies were identified and included. Cost-effectiveness analyses of varicella zoster vaccination were excluded. The quality of the included studies ranged from ‘moderate’ to ‘moderate to good’ according to the British Medical Journal guidelines of Drummond and Jefferson and the Quality of Health Economic Studies (QHES) score of Ofman et al. Most studies evaluated the cost effectiveness of universal HZ vaccination in adults aged 50 years or 60 years and older. Data sources and model assumptions regarding epidemiology, utility estimates and costs varied between studies. All studies calculated costs per QALY, which allows comparing costs of interventions in different diseases. The costs per QALY gained and the incremental cost-effectiveness ratio (ICER) differed between studies depending on the age at vaccination, duration of vaccine efficacy, cost of vaccine course and economic perspective. All but one of the studies concluded that most vaccination scenarios are cost effective and the vaccination of specific subgroups such as the older age group is most cost effective.


Model input parameters such as age at vaccination, vaccine costs, HZ incidence, PHN length and duration of vaccine efficacy had a great impact on the estimated cost effectiveness of HZ vaccination. To compare the results of different cost-effectiveness studies of HZ vaccination, uniform methods should be used and the most important input parameters used for the different models should be critically assessed.

Supplementary material

40273_2012_20_MOESM1_ESM.pdf (285 kb)
Supplementary material 1 (PDF 284 kb)


  1. 1.
    Bennett GJ, Watson CPN. Herpes zoster and post-herpetic neuralgia: past, present, and future. Pain Res Manage. 2009;14(4):275–82.Google Scholar
  2. 2.
    Wilson JF. Herpes zoster. Ann Intern Med. 2011;154(5):3–15.Google Scholar
  3. 3.
    Benbernou A, Drolet M, Levin MJ, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain. 2011;15(10):1100–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Boivin G, Jovey R, Elliott CT, et al. Management and prevention of herpes zoster: a Canadian perspective. Can J Infect Dis Med Microbiol. 2010;21(1):45–52.PubMedGoogle Scholar
  5. 5.
    Drolet M, Brisson M, Levin MF, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–66.PubMedGoogle Scholar
  6. 6.
    Chiappe SG, Sarazin M, Turbelin C, et al. Herpes zoster: burden of disease in France. Vaccine. 2010;28(50):7933–8.CrossRefGoogle Scholar
  7. 7.
    Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl. 1):2–7.CrossRefGoogle Scholar
  8. 8.
    Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.PubMedCrossRefGoogle Scholar
  9. 9.
    Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.PubMedCrossRefGoogle Scholar
  10. 10.
    Hurley LP, Harpaz R, Daley MF, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl. 2):216–23.CrossRefGoogle Scholar
  11. 11.
    Lu P, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):1–6.CrossRefGoogle Scholar
  12. 12.
    Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67(2–3):241–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731–6.PubMedGoogle Scholar
  17. 17.
    Mick G, Gallais JL, Simon F, et al. Burden of herpes zoster and post-herpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over [in French]. Rev Epidemiol Sante Publique. 2010;58(6):393–401.PubMedCrossRefGoogle Scholar
  18. 18.
    Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics. 2003;21(1):13–38.PubMedCrossRefGoogle Scholar
  19. 19.
    Centers for Disease Control and Prevention. Childhood immunization schedule, 2011. Atlanta: CDC; 2011. Accessed 1 Sept 2011.
  20. 20.
    Centers for Disease Control and Prevention. Adult immunization schedule, 2011. Atlanta: CDC. Accessed 1 Sept 2011.
  21. 21.
    Sanford M, Keating GM. Zoster vaccine (Zostavax®): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Levin MJ, Gershon AA, Dworkin RH, et al. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010;48(Suppl. 1):14–9.CrossRefGoogle Scholar
  24. 24.
    Oxman MN, Levin MJ, et al. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl. 2):228–36.CrossRefGoogle Scholar
  25. 25.
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61.PubMedGoogle Scholar
  27. 27.
    Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23–24):3076–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317–25.PubMedCrossRefGoogle Scholar
  29. 29.
    Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326–37.PubMedCrossRefGoogle Scholar
  30. 30.
    Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4(3):238–45.PubMedCrossRefGoogle Scholar
  32. 32.
    Najafzadeh M, Marra CA, Galanis E, et al. Cost-effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991–1004.PubMedCrossRefGoogle Scholar
  33. 33.
    van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.PubMedCrossRefGoogle Scholar
  34. 34.
    Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8:7.PubMedCrossRefGoogle Scholar
  36. 36.
    van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.PubMedCrossRefGoogle Scholar
  37. 37.
    van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet. 2006;367:219–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Michel JP, Kempf W. Data collection related to the management of herpes zoster (HZ) and post-herpetic neuralgia (PHN) and demographic parameters in Switzerland 2007 [unpublished].Google Scholar
  40. 40.
    Wasem J, Lang K, Papageorgiou M, et al. Health economic evaluation of a new vaccine for the prevention of herpes zoster and post-herpetic neuralgia in adults a German analysis [abstract no. PIH22]. Value Health. 2009;12(7):A294.CrossRefGoogle Scholar
  41. 41.
    Ollendorf PA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. Med Care. 2010;48(6 Suppl.):145S–52S.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Institute of Pharmaceutical Medicine/European Center of Pharmaceutical Medicine (ECPM)University of BaselBaselSwitzerland

Personalised recommendations